53 research outputs found
ELECTROPHORETIC SEPARATION OF MULTIPLE FORMS OF PARTICLE ASSOCIATED ACID PHOSPHATASE
No full textThe acid phosphatases of rat liver mitochondrial-lysosomal fractions have been examined by quantitative and electrophoretic means. Disruption of mitochondrial-lysosomal material by freeze-thawing, sonication, or by blendor treatment released approximately 55.0 to 65.0 per cent of the total acid phosphatase activity of the fraction into the unsedimentable phase. Electrophoretic preparations of this material showed a single acid phosphatase-active site. Treatment of mitochondrial-lysosomal fractions with 5.0 per cent Triton X-100 released 98.0 per cent of the total acid phosphatase activity of the fraction into the unsedimentable phase. Electrophoretic preparations of this material showed two major sites of acid phosphatase activity. One of these was identical to that resolved following physical disruption. The other site was characteristically seen only after treatment with Triton X-100. This acid phosphatase was also released by treatment with digitonin but to a lesser extent. Quantitative and electrophoretic examination indicated that both components of acid phosphatase were concentrated in the mitochondrial-lysosomal fraction. Physical separation of the acid phosphatase released by detergent treatment from the acid phosphatase released by physical disruption was achieved. It was concluded that two categories of acid phosphatase may reside in lysosomal particles. These phosphatases differ in the nature of their binding to lysosomal structure as well as in their electrophoretic properties.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72869/1/j.1749-6632.1964.tb14230.x.pd
Measurement of the Third Component of Complement Bound to Red Blood Cells in Patients with the Cold Agglutinin Syndrome
No full text
Abstract CT207: Phase I dose escalation and pharmokinetic study of 14-O-phosphonooxymethyltriptolide
No full text
Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma
No full textPTK787/ZK222584 (Vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGF-Rs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once daily PTK787/ZK222584 at a target dose of 1250mg. Eighteen patients were evaluable for response: 1 patient had a complete response (CR), 6 patients had stable disease but subsequently progressed, 10 patients had progressive disease by 3 cycles, and 1 subject withdrew before response evaluation. The patient who attained a CR underwent autologous stem cell transplantation and remains disease free 76 months after study completion. There were no grade 4 toxicities. Grade 3 thrombocytopenia occurred in 20% and grade 3 hypertension occurred in 10%. There were no episodes of grade 3 proteinuria. In conclusion, PTK787/ZK222584 was well tolerated in a heavily pretreated population of DLBCL patients, though its therapeutic potential as a single agent in DLBCL appears limited
- …
